Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Related articles:
Related suggestion:
10 major criminal suspects transferred back to China from MyanmarWerder Bremen accuses Naby Keita of walking out on the team for Leverkusen gameMeeting for Mount Qomolangma guides held to share skills, stories in LhasaChina offers winter comfort to people in needChina moves to improve grassroots access to basic medical servicesCriminal cases involving guns, explosives down 20 pct in ChinaChina to further enhance medical treatment for critical pregnant womenTottenham and Man United advance to Women's FA Cup final in EnglandChina to further enhance medical treatment for critical pregnant womenEarthquake leaves 13 dead in China's Qinghai
2.4105s , 6491.765625 kb
Copyright © 2024 Powered by Chinese inhibitor drug candidate becomes first to enter phase ,Global Gazetteer news portal